Clinical Trial Search

Primary: Participants With Adverse Events (AEs) up to 72 Hours Post-dosing — 2; 1; 2 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants

Primary: Change in Mean Glucagon Concentration During Induced Hypoglycemia From Target Plasma Glucose (PG) Concentration of 100 Milligrams Per Deciliter (mg/dL) to a Nadir Target…

Primary: Number of Participants With Unsolicited Treatment Emergent Adverse Events (TEAEs) Through Day 151 — 1; 2; 3; 3 Participants

Primary: Rate of Local Solicited Adverse Events After Each Study Vaccination — 13; 17; 11; 23 Participants

Primary: Number of Participants With Adverse Events — 3; 2; 3; 7 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of Midazolam and 1-hydroxymidazolam — 22.0; 18.5; 9.92; 7.97 ng/mL

Primary: Occurrence of All Serious Adverse Events (SAEs) at Any Time During the Study — 0; 0; 0 Serious Adverse Event

Primary: Feasibility of Enrollment: Percent of Participants Enrolled — 19 Participants

Primary: Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Gray (Gy) — 36.4; 44.2; 47.1 Gray (Gy)

Primary: AUCinf of Nirmatrelvir Following the Administration of Nirmatrelvir/Ritonavir in Different Delivery Vehicles — 27090; 30650; 33030; 34000 nanogram*hour per milliliter…

Primary: Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961 — 38.80; 38.67; 39.19; 56.68 nanograms/milliliter (ng/mL)

Primary: The Incidence, Severity and Relationship of Treatment-Emergent Adverse Events (TEAEs). — 10; 7; 4; 5 participants

Primary: Characterize the PK/PD Relationship Between OZ439 and PQP Plasma Concentrations (Cmax) — 0.2582; 0.4145; 0.8829; 0.6835 ng/L

Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-∞) of Plasma N-Hydroxycitidine (NHC) — 8930; 10900 hr*ng/mL